Dyax Announces Positive Final Results from Phase I Trial of Subcutaneous DX-88
Positive Experience with Subcutaneously Administered DX-88 in the Ongoing, Phase II Open-Label EDEMA2 Trial for Hereditary Angioedema
Based on the pharmacokinetic and safety profiles observed in the Phase I trial, Dyax has now converted all clinical sites in the ongoing EDEMA2 trial from intravenous (IV) dosing to the more easily administered subcutaneous (SQ) injection of DX-88. This conversion has provided HAE patient experience with SQ DX-88 prior to the initiation of a pivotal Phase III trial planned to start before year end. Recently, Dyax has sent the Phase III protocol to 47 U.S. and Canadian sites. Dyax expects the IRB approval process to go smoothly and already has sites with identified patients, awaiting enrollment. Dyax, together with Genzyme, remains committed to bringing DX-88 to the marketplace as the first subcutaneously administered treatment for the HAE patient community.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.